Sotera Health Co Dossier
Qualitative Analysis
Business overview
Sotera Health Co. (NASDAQ: SHC) is a leading global provider of mission-critical end-to-end sterilization solutions, lab testing, and advisory services for the healthcare industry. Operating under its core mission of "Safeguarding Global Health®," the company serves more than 40 of the top 50 medical device companies and nine of the top ten global pharmaceutical companies. Sotera Health operates through three highly integrated business segments: Sterigenics, which provides outsourced terminal sterilization and irradiation services; Nordion, a leading global supplier of Cobalt-60 used in gamma sterilization and cancer treatments; and Nelson Labs, which offers outsourced microbiological and analytical chemistry testing and advisory services. The company's services are deeply embedded in its customers' manufacturing processes and regulatory supply chains, creating high switching costs and a highly defensive, recurring revenue model.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A multi-year capital investment program focused on expanding sterilization facilities and building new centers in high-growth regions to capture increasing medical device sterilization demand.
Expected impact: Expands global sterilization capacity across multiple modalities (Gamma, EO, E-beam) to meet rising demand from medical device manufacturers.
Nelson Labs' launch and expansion of product-sterility testing using rapid microbiological methods (RMMs) across three laboratory sites in the United States and Europe.
Expected impact: Reduces product sterility incubation times from the traditional 14 days to as little as 6 days, enabling faster product release to market for medical device and pharmaceutical manufacturers.
Nelson Labs' launch of RapidCert™, an innovative rapid biological indicator (BI) sterility testing service utilizing a combination of traditional BIs and rapid microbiological methods.
Expected impact: Reduces biological indicator incubation times to 48 hours (down from 7 days), allowing manufacturers to confirm sterility for lot release and sterilization validations in as little as three days.
A strategic initiative to double the cleanroom capacity at Nelson Labs to support growing global demand for sterility assurance services.
Expected impact: Significantly increases throughput and capacity for sterility assurance testing, supporting the broader medical device and pharmaceutical validation pipeline.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Establishes the first commercial-scale production of Cobalt-60 in U.S. Pressurized Water Reactors (PWRs) at PSEG's Salem Nuclear Generating Station. This initiative aims to secure a reliable, domestic supply of Cobalt-60, meeting 50-100% of U.S. demand by the mid-2030s and eliminating reliance on Russian-sourced isotopes.
Terms: Long-term commercial agreements entered into to implement newly developed Cobalt-60 production technology, with Cobalt-60 planned to be supplied to Nordion.